Clarithromycin PCD Pharma Franchise Company
Cafoli Lifecare offers a Clarithromycin range of 10 formulations across tablets, dry syrup and injection, manufactured in WHO-GMP certified facilities. Distributors building an antibiotic portfolio can secure district-wise monopoly franchise rights on this widely used macrolide.
What is Clarithromycin?
Clarithromycin is a semi-synthetic macrolide antibiotic that inhibits bacterial protein synthesis by binding the 50S ribosomal subunit, active against respiratory pathogens, atypical organisms and Helicobacter pylori. It is listed on the WHO Model List of Essential Medicines. More information is on MedlinePlus.
Therapeutic Applications
Clarithromycin is used for community-acquired pneumonia, bronchitis, sinusitis, pharyngitis, skin and soft tissue infections, and as part of H. pylori eradication regimens. Prescribers include pulmonologists, ENT specialists, gastroenterologists, general physicians and paediatricians.
Why Clarithromycin is a High-Potential Molecule for Distributors
As a first-choice macrolide for respiratory infection and a fixed component of H. pylori triple therapy, clarithromycin draws demand from both the respiratory and gastro segments. Dry syrup adds paediatric reach while injection serves inpatient use, letting franchise partners address multiple specialties and age groups with a single, high-trust antibiotic.
Why Choose Cafoli Lifecare
Cafoli Lifecare is a WHO-GMP compliant, DCGI-approved PCD pharma company with 1000+ franchise partners across India. Partners receive district-wise monopoly rights, promotional inputs including visual aids, MR bags and product cards, and consistent stock availability backed by quality-tested manufacturing.
References
- MedlinePlus: Clarithromycin
- PubChem: Clarithromycin
- WHO Model List of Essential Medicines
Our formulations of Clarithromycin find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: